DNDi South Asia
DNDi started its activities in South Asia in 2004 to build and strengthen regional partnerships to carry out R&D for neglected diseases in the region. DNDi has activities in India and Bangladesh, mainly focused on visceral leishmaniasis and conducting clinical trials and capacity-building initiatives. More recently, DNDi South Asia started to be active in the fields of paediatric HIV and early drug discovery for leishmaniasis.
- Lead Optimization Consortium in India (LOCI)
- LXE408 Novartis
- New treatments for PKDL
- New treatments for HIV/VL
- New VL treatments (South Asia)
DNDi South Asia
PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
Tel: +91 11 4550 1795
- Supported the Indian National Kala-azar Elimination Programme in building capacity to diagnose kala-azar (visceral leishmaniasis) and post-kala-azar dermal leishmaniasis (PKDL), and by gathering evidence needed to respond to threats to the sustainable elimination of visceral leishmaniasis in the region.
- Completed recruitment for a clinical trial for PKDL, testing amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected by mid-2020.
- Partnered in an MSF study on kala-azar-HIV co-infection in Bihar state to evaluate treatments with amphotericin B monotherapy and an amphotericin B -miltefosine combination, with results expected in 2019 that will provide key evidence to national and regional decision-makers on the best treatment for co-infected patients.
- Launched GARDP’s 11-country observational study to collect clinical information on treatment of babies with sepsis, to guide the development of new and improved antibiotic treatments for newborns.